MoonLake Immunotherapeutics (MLTX) Competitors $42.32 +0.88 (+2.12%) Closing price 04:00 PM EasternExtended Trading$42.60 +0.28 (+0.66%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. VTRS, QGEN, ROIV, RVMD, LNTH, BBIO, TGTX, LEGN, SRPT, and TLXShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), and Telix Pharmaceuticals Limited American Depositary Shares (TLX). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Viatris Qiagen Roivant Sciences Revolution Medicines Lantheus BridgeBio Pharma TG Therapeutics Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Viatris (NASDAQ:VTRS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking. Is VTRS or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Viatris' net margin of -5.87%. Viatris' return on equity of 16.46% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-5.87% 16.46% 7.09% MoonLake Immunotherapeutics N/A -15.54%-15.09% Do institutionals & insiders have more ownership in VTRS or MLTX? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, VTRS or MLTX? Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Does the media favor VTRS or MLTX? In the previous week, Viatris had 21 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 33 mentions for Viatris and 12 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.74 beat Viatris' score of 0.01 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 4 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 5 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend VTRS or MLTX? Viatris presently has a consensus target price of $10.50, indicating a potential upside of 21.39%. MoonLake Immunotherapeutics has a consensus target price of $80.50, indicating a potential upside of 90.22%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75MoonLake Immunotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better earnings and valuation, VTRS or MLTX? Viatris has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.70$54.70M-$0.53-16.32MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.89-22.39 Does the MarketBeat Community prefer VTRS or MLTX? MoonLake Immunotherapeutics received 46 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 82.14% of users gave MoonLake Immunotherapeutics an outperform vote while only 34.85% of users gave Viatris an outperform vote. CompanyUnderperformOutperformViatrisOutperform Votes2334.85% Underperform Votes4365.15% MoonLake ImmunotherapeuticsOutperform Votes6982.14% Underperform Votes1517.86% SummaryMoonLake Immunotherapeutics beats Viatris on 11 of the 18 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.71B$6.84B$5.55B$8.04BDividend YieldN/A2.95%5.09%4.22%P/E Ratio-32.817.4422.6818.83Price / SalesN/A257.63404.28106.72Price / CashN/A65.8538.1834.62Price / Book5.196.576.794.33Net Income-$36.01M$143.14M$3.22B$247.97M7 Day Performance7.36%3.60%2.44%2.71%1 Month Performance11.22%6.01%3.79%3.37%1 Year Performance-0.59%-2.02%17.06%5.80% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics1.5442 of 5 stars$42.32+2.1%$80.50+90.2%-3.3%$2.71BN/A-32.812Upcoming EarningsAnalyst ForecastPositive NewsVTRSViatris1.6913 of 5 stars$8.25+1.5%$10.50+27.3%-27.2%$9.85B$14.74B-11.1537,000Upcoming EarningsQGENQiagen3.8208 of 5 stars$42.49+1.0%$47.83+12.6%+1.4%$9.45B$1.98B118.316,030Upcoming EarningsGap UpROIVRoivant Sciences2.2085 of 5 stars$11.19+1.6%$17.50+56.4%+3.3%$7.98B$122.59M-74.60860RVMDRevolution Medicines3.769 of 5 stars$41.47+7.0%$66.67+60.8%+4.7%$7.71B$742,000.00-11.55250Upcoming EarningsPositive NewsLNTHLantheus3.9942 of 5 stars$102.70+0.9%$129.43+26.0%+57.2%$7.03B$1.53B17.09700Upcoming EarningsPositive NewsBBIOBridgeBio Pharma4.5814 of 5 stars$35.89-1.2%$53.00+47.7%+42.1%$6.81B$221.90M-12.59400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageTGTXTG Therapeutics3.3393 of 5 stars$42.03+1.7%$40.67-3.2%+185.7%$6.67B$329.00M-420.26290Upcoming EarningsPositive NewsLEGNLegend Biotech2.5246 of 5 stars$34.70+1.2%$78.82+127.1%-22.8%$6.37B$627.24M-36.531,070Positive NewsSRPTSarepta Therapeutics4.7694 of 5 stars$61.51+1.8%$158.70+158.0%-52.0%$5.97B$1.90B49.21840Upcoming EarningsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies VTRS Competitors QGEN Competitors ROIV Competitors RVMD Competitors LNTH Competitors BBIO Competitors TGTX Competitors LEGN Competitors SRPT Competitors TLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLTX Stock Free MLTX Stock Alerts